HOME >> MEDICINE >> NEWS
ReQuip cuts risk of dyskinesias by 15-fold in early Parkinson's disease

Vancouver, Canada - A landmark, multinational, 5-year study shows that the dopamine-agonist ReQuip® (ropinirole hydrochloride, SmithKline Beecham) is associated with a much lower incidence of dyskinesias than L-dopa, and has comparable efficacy to L-dopa in the management of early Parkinson's Disease. The results of this exciting study are released today for the first time at the XIII International Congress on Parkinson's Disease (ICPD), Vancouver, 24-28 July, 1999.

"This landmark study should affect the future management of Parkinson's Disease. The data demonstrate that ropinirole is a first-line option for the initial treatment of early Parkinson's Disease," commented lead author of the study, Professor Olivier Rascol, Professor of Pharmacology at the Centre Hospitalier Universitaire, Toulouse, France.

"This is important news for patients, as we can now hope for good control of their symptoms with less risk of dyskinesias," concluded Dr Donald Calne, Chairman of the ICPD, and Director of the Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, Canada.

The 268 patients participating in this double-blind controlled study, conducted in Europe, Israel and Canada, were randomised to receive either ReQuip® or L-dopa -- the current standard therapy. Both treatment groups were allowed to receive supplementary L-dopa if required.

The study demonstrated that the probability (odds ratio) of developing dyskinesias was 3.8 times higher for patients receiving L-dopa (incidence 46%) than for patients receiving ReQuip®, either alone or with additional L-dopa (incidence 20%). In patients who completed the trial on ReQuip® alone, the benefit was found to be even greater, with the relative probability of dyskinesias 15.2 times higher in the L-dopa group (incidence 36%) than the ReQuip® group (incidence 5%).

Over the 5-year study period, both groups of patients experienced similar control of their symptoms. A
'"/>

Contact: Kate Davies (Vancouver)
alexa@meditech.co.uk
44-780-840-345
MediTech Media Ltd.
26-Jul-1999


Page: 1 2

Related medicine news :

1. Clozapine effective for controlling dyskinesias in people with severe Parkinsons
2. New marker for early diagnosis of kidney failure identified
3. English-speaking Hispanic youth more likely to have sex early
4. Inpatient smoking cessation counseling is associated with early differences in mortality
5. Study finds no reason for expectant mothers to shy away from early epidurals
6. No increase in C-sections when epidural analgesia given early in labor
7. Radiologists offer non-surgical treatment for early-stage liver cancer
8. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
9. A new method for early detection of disease outbreaks
10. UCLA study: Nearly a third of drug ads in medical journals contain no references for medical claims
11. Morbidly obese pay nearly twice as much for health care

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ReQuip cuts risk dyskinesias fold early Parkinson disease

(Date:3/6/2015)... FCPX developers have announced a ... , “Pro3rd Hue is a lower 3rd pack with a ... Film Studios. “Blurring the line between professional and armature, Pro3rd ... a set of 30 customizable lower third presets made exclusively ... FCPX users can complement any design with a clean and ...
(Date:3/6/2015)... 06, 2015 Dr. Mark Sowell recently returned ... Scottsdale, AZ. Offering programs for advanced education in the field ... world. , As a visiting faculty member of this ... learn” each time he visits Spear Education to participate in ... remarks, “we are training only the top 10% and those ...
(Date:3/6/2015)... March 06, 2015 As the Mayo ... be discussed, Ford & Associates Nationwide Legal Services, A.P.C., ... 2015 filed lawsuit: Verduzco v. Daiichi Sankyo, Inc., Case ... California. , “In light of a recently filed ... Benicar to evaluate and explore the Mayo Clinic's Benicar ...
(Date:3/5/2015)... 2015 In 2014, the FDA approved ... tops the list scoring 4 drug approvals in the ... all FDA approved drug products, followed by oncology therapy ... anti-PCSK9, anti-PD1 and CDK inhibitors keep on attracting large-cap ... FDA to treat metastatic melanoma, and at present, they ...
(Date:3/5/2015)... Diego, CA (PRWEB) March 05, 2015 ... levels of formaldehyde in low-cost laminate flooring ... the leading manufacturer of eco-friendly building materials made ... customer safety by testing all their flooring products ... emissions detection laboratory Benchmark International (BMH). ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 2Health News:World Pharma Business and Large-Cap Companies Discussed by MP Advisors in In-demand Study Available at MarketPublishers.com 3Health News:With Homeowners Concerned About Formaldehyde, Cali Bamboo Puts Safety Above Bottom Line 2
(Date:3/5/2015)... BAUDETTE, Minn. , March 5, 2015 /PRNewswire/ ... ) today announced that it has acquired the ... Acetate tablets USP 50mg, 100mg and 150mg, previously ... the overall market for this product was approximately ... Arthur S. Przybyl , President and CEO of ...
(Date:3/5/2015)... and Markets ( http://www.researchandmarkets.com/research/4q7gwz/india_pharma ) has announced ... Accelerating growth to the next level - Moving up ... offering. Domestic sales improved in 2014, ... the market,s reaction to the new drug pricing policy. ... healthy, as the momentum continues and improving economic growth ...
(Date:3/5/2015)... 2015 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing products that address unmet medical needs in the ... its President and Chief Executive Officer, Christopher J. ... the 27 th Annual ROTH Conference in ... 10, 2015 at 1:00 PM Pacific Daylight Time (PDT).  ...
Breaking Medicine Technology:ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 2ANI Pharmaceuticals Acquires Generic Drug Product from Teva Pharmaceuticals 3India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3
Cached News: